700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Investor Presentation
Annual Meeting Results - Stockholders Elect Class I Directors
Reports First Quarter 2026 Financial Results and Operational Highlights
Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
License Agreement with Pfizer for Matrix-M Technology
Reports Third Quarter 2025 Financial Results and Operational Highlights
Completes U.S. Marketing Authorization Transfer for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Definitive Additional Information Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Submission Upload
Definitive Revised Proxy Statement
Free Writing Prospectus
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence